PT1113015E - Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d - Google Patents

Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d

Info

Publication number
PT1113015E
PT1113015E PT00311130T PT00311130T PT1113015E PT 1113015 E PT1113015 E PT 1113015E PT 00311130 T PT00311130 T PT 00311130T PT 00311130 T PT00311130 T PT 00311130T PT 1113015 E PT1113015 E PT 1113015E
Authority
PT
Portugal
Prior art keywords
piperazinylphenyl
trifluoromethyl
optically active
phenyl
methyl
Prior art date
Application number
PT00311130T
Other languages
English (en)
Inventor
Stephane Caron
Adam Mavis Diane
Howard Harry Ralph Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT1113015E publication Critical patent/PT1113015E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
PT00311130T 1999-12-29 2000-12-13 Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d PT1113015E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17343799P 1999-12-29 1999-12-29

Publications (1)

Publication Number Publication Date
PT1113015E true PT1113015E (pt) 2004-12-31

Family

ID=22632024

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00311130T PT1113015E (pt) 1999-12-29 2000-12-13 Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d

Country Status (9)

Country Link
US (2) US20010039280A1 (pt)
EP (1) EP1113015B1 (pt)
JP (1) JP3495708B2 (pt)
AT (1) ATE276249T1 (pt)
CA (1) CA2329576A1 (pt)
DE (1) DE60013751T2 (pt)
DK (1) DK1113015T3 (pt)
ES (1) ES2225031T3 (pt)
PT (1) PT1113015E (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529117A (ja) * 2002-04-19 2005-09-29 グラクソ　グループ　リミテッド ５ＨＴ２ｃ受容体に対する親和性を有する化合物及びその治療における使用
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
EP1836164B1 (en) * 2005-01-13 2011-08-24 GE Healthcare Limited 11c-labeled benzyl-lactam compounds and their use as imaging agents
JPWO2006104280A1 (ja) * 2005-03-31 2008-09-11 武田薬品工業株式会社 糖尿病の予防・治療剤
WO2007012964A1 (en) * 2005-07-25 2007-02-01 Pfizer Products Inc. Preparation of alkylpiperazinylphenyl compounds by classical resolution
WO2007026224A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. 5-ht1b antagonist composition for depression, anxiety and cognition
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
FR2670491B1 (fr) * 1990-12-14 1993-02-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les renfermant.
FR2692264B1 (fr) * 1992-06-12 1994-08-05 Adir Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
EA001485B1 (ru) * 1996-03-29 2001-04-23 Пфайзер Инк. Производные бензил(иден)-лактамов, их получение и применение в качестве селективных (ант)агонистов рецепторов 5-htи/или 5-ht

Also Published As

Publication number Publication date
JP3495708B2 (ja) 2004-02-09
EP1113015B1 (en) 2004-09-15
CA2329576A1 (en) 2001-06-29
EP1113015A1 (en) 2001-07-04
ATE276249T1 (de) 2004-10-15
US20010039280A1 (en) 2001-11-08
US20030083337A1 (en) 2003-05-01
DE60013751T2 (de) 2005-09-29
ES2225031T3 (es) 2005-03-16
DE60013751D1 (de) 2004-10-21
DK1113015T3 (da) 2004-12-13
EP1113015A4 (en) 2001-03-23
JP2001187781A (ja) 2001-07-10

Similar Documents

Publication Publication Date Title
JP2008110984A5 (pt)
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
WO2005092307A3 (en) Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
ATE303369T1 (de) Glucocorticoid rezeptor modulatoren
UA93209C2 (ru) Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема
EA200601378A1 (ru) Гидроизоиндолиновые антагонисты рецептора тахикинина
CA2252898A1 (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one(=ziprasidone), its preparation and its use as dopamine d2 antagonist
ATE327974T1 (de) Modulatoren des glucocorticoid-rezeptors
SG164283A1 (en) New benzimidazole derivatives
YU37203A (sh) Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
PT1113015E (pt) Compostos 3-((2-piperazinilfenil)metil)-1-(4-(trifluorometil)fenil)-2-pirrolidinona opticamente activos, como antagonistas selectivos dos receptores de 5-ht1d
ATE313539T1 (de) Chinolin-4-carboxamidderivate als nk-3 und nk-2 rezeptor antagonisten
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
SE0002729D0 (sv) Novel compound form
ATE434437T1 (de) Verwendung von antagonisten der 5-ht3-rezeptoren zur behandlung von muskuloeskeletalen erkrankungen
CL2008003066A1 (es) Compuestos derivados de 1-[3-(fenilamino)-5-(piridin-4-il)-1h-1,2,4-triazol-1-il]-alquil-2-ol; composición farmacéutica; procedimiento de preparación de dicha composición; y uso para el tratamiento o prevención de una enfermedad del sistema nervioso central.
ATE362364T1 (de) Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
RU2003115431A (ru) Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина
SE9900190D0 (sv) New compounds
WO2007030589A3 (en) Pharmaceutical dosage forms and compositions comprising lecoztan